Clinical trials: Bortezomib
Melanoma, Soft Tissue Sarcoma
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.
- Conditions
- Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung
- Trial name
- NCT00580320
- Testing
- Dacarbazine and bortezomib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
Multiple Myeloma
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with…
- Trial name
- NCT02928029
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Bortezomib, Dexamethasone
- Where
- 7 sites in United States, South Korea and 1 more
- Volunteers
- 7 people
- Sponsor
- Bayer
Relapsed or Refractory Multiple Myeloma
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose.
- Trial name
- NCT00708292
- Testing
- AUY922, Bortezomib, Dexamethasone
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Primary Systemic Amyloidosis, Light Chain Deposition Disease
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease.
- Trial name
- NCT00520767
- Testing
- bortezomib, dexamethasone, melphalan
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Breast Cancer
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Primary objective is to determine the effectiveness of the combination of bortezomib and doxorubicin in patients with metastatic breast cancer.
- Trial name
- NCT00574236
- Testing
- PS-341, doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of elotuzumab and to see how well it works when given together with lenalidomide, bortezomib, and dexamethasone in treating patients with newly…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
- Trial name
- NCT01668719
- Testing
- Bortezomib, Dexamethasone, Elotuzumab
- Where
- 417 sites in United States
- Volunteers
- 142 people
- Sponsor
- SWOG Cancer Research Network
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma
- Trial name
- NCT01267812
- Testing
- bortezomib, rituximab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Phase III multicenter randomized, open-label study comparing the efficacy of a combined high dose chemotherapy using melphalan and bortezomib versus melphalan alone followed by stem cell transplant in frontline multiple myeloma…
- Trial name
- IFM2014-02 (NCT02197221)
- Testing
- Bortezomib-Melphalan, Melphalan
- Where
- 46 sites in Belgium, France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Toulouse
Peripheral T-cell Lymphoma
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
The purpose of this study is to determine the efficacy and the safety profile and toxicity of a combination of Velcade™ (bortezomib) with a standard chemotherapy regimen (ACVBP [doxorubicin, cyclophosphamide, vindesine…
- Trial name
- NCT00136565
- Testing
- Velcade, Doxorubicin, Prednisone
- Where
- 5 sites in Belgium, France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Advanced Non-Small Cell Lung Cancer, Other Solid Tumors
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
The purpose of this study is to evaluate how safe VELCADE (PS-341) is when given with Taxotere (Docetaxel) to patients with non-small cell lung cancer or other solid tumors, and also to see what effects (good and bad) it has on…
- Trial name
- NCT00064636
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Volunteers
- 46 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Multiple Myeloma
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose melphalan and prednisone (VMP) or with…
- Trial name
- NCT01190787
- Testing
- velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade prednisone
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate efficacy and safety of the combination regimen of bortezomib-bendamustine-dexamethasone in patients with relapsed or refractory multiple myeloma
- Trial name
- BBD (NCT01168804)
- Testing
- bendamustine plus bortezomib plus dexamethasone
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 79 people
- Sponsor
- Austrian Forum Against Cancer
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell…
- Conditions
- Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma
- Trial name
- NCT02112916
- Testing
- Bortezomib, Cyclophosphamide, Cytarabine
- Where
- 212 sites in United States, Australia and 2 more
- Volunteers
- 847 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin…
- Trial name
- NCT00750815
- Testing
- Cyclophosphamide, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone, etoposide, and cytarabine, work in different ways to stop the…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01127009
- Testing
- bortezomib, mitoxantrone hydrochloride, etoposide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center